The Tencent-backed owner of pharmaceutical platform Miaoshou Doctor has raised a series F round from new and returning investors, six months after it completed a series E.

The multi-corporate-backed biologic pill developer has listed on the Nasdaq Global Market, pricing the shares below their range.

Pulse Medical and BioMap are among the companies that raised nine-figure rounds, while Amwell bought two corporate-backed companies at once.

Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.

SoftBank and Heritage Provider Network were among the investors who co-led a series C round for Intervenn Biosciences, which is developing precision medicine.

The MDC spinout raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.

The developer of T-cell receptor therapies backed by Boehringer Ingelheim raised a series B round which will be used to boost its manufacturing capacity and advance its pipeline of candidates.

Corporate-backed teleconferencing system provider Baijiayun raised cash at a $465m valuation while financial software provider Prime Trust closed a $64m round featuring Nationwide and Samsung Next.

UW's vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.

The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.